pages=[OCRPageObject(index=0, markdown="# $\\rightarrow$ atna \n\n## MEDICARE FORM\n\nRiabni ${ }^{\\circledR}$ (rituximab-arrx), Rituxan ${ }^{\\circledR}$ (rituximab), Ruxience (rituximab-pvvr), Truxima (rituximab-abbs) Medication Precertification Request Page 1 of 5\n(All fields must be completed and legible for precertification review.)\n\nFor Medicare Advantage Part B: For other lines of business: Please use commercial form.\n\nNote: Riabni and Rituxan are nonpreferred. The preferred biosimilar products are Ruxience and Truxima. For rheumatoid arthritis, all Rituxan and biosimilar products are non-preferred.\n\nWould you like to use electronic prior authorization? Consider using Availity, our electronic prior authorization portal. Learn more about Availity from the links in the table below.\n\nFor phone or fax requests, refer to the table below for routing information. To determine which box to use, refer to the patient's Aetna ID card. State specific special needs and Medicare-Medicaid Plans may be designated on the front of the ID card or in the website URL on the back of the card. If you don't see your specific plan listed, call the number on the back of the member's ID card to confirm routing information.\n\nFor Aetna Medicare Advantage and Allina Health Aetna Medicare members send request to:\nPhone: 1-866-503-0857 (TTY: 711)\nFax: $\\quad 1-844-268-7263$\nAvaility: https://www.aetna.com/health-care-professionals/resource-center/availity.html\nFor Aetna Medicare Advantage Virginia Dual Eligible Special Needs Plans (HMO D-SNP) send request to:\nPhone: $\\quad 1-855-463-0933$\nFax: $\\quad 1-833-280-5224$\nAvaility: https://www.aetnabetterhealth.com/virginia-hmosnp/providers/portal\nFor Aetna Assure Premier Plus Medicare Advantage New Jersey Dual Eligible Special Needs Plans (HMO D-SNP) send request to:\nPhone: $\\quad 1-844-362-0934$\nFax: $\\quad 1-833-322-0034$\nAvaility: https://www.aetnabetterhealth.com/new-jersey-hmosnp/providers/portal.html\nFor Aetna Better Health of Illinois Premier Medicare Medicaid Plan (MMP) send request to:\nPhone: $\\quad 1-866-600-2139$\nFAX: $\\quad 1-855-320-8445$\nAvaility: https://www.aetnabetterhealth.com/illinois/providers/portal\nFor Aetna Better Health of Ohio Premier Medicare Medicaid Plan (MMP) send request to:\nPhone: $\\quad 1-855-364-0974$\nFax: $\\quad 1-855-734-9389$\nAvaility: https://www.aetnabetterhealth.com/ohio/providers/portal\nFor Aetna Better Health of Michigan Premier Medicare Medicaid Plan (MMP) send request to:\nPhone: $\\quad 1-855-676-5772$\nFax: $\\quad 1-844-241-2495$\nAvaility: https://www.aetnabetterhealth.com/michigan/providers/portal.html", images=[], dimensions=OCRPageDimensions(dpi=200, height=2200, width=1700)), OCRPageObject(index=1, markdown="# MEDICARE FORM\nRiabni® (rituximab-arrx),\nRituxan® (rituximab), Ruxience\n(rituximab-pvvr), Truxima (rituximab-abbs)\nMedication Precertification Request\nPage 2 of 5\n(All fields must be completed and return both pages for precertification review.)\nFor Medicare Advantage Part B:\nFor other lines of business:\nPlease use commercial form.\nNote: Riabni and Rituxan are non-\npreferred. The preferred biosimilar\nproducts are Ruxience and Truxima.\nFor rheumatoid arthritis, all Rituxan and\nbiosimilar products are non-preferred.\nPlease indicate: ☐ Start of treatment, start date: _____/____/_____ ☐ Continuation of therapy, date of last treatment: _____/____/____/_____\nPrecertification Requested By: Phone: Fax: ______________________________\n\nA. PATIENT INFORMATION\nFirst Name: Last Name: DOB:\nAddress: City: State: ZIP:\nHome Phone: Work Phone: Cell Phone: E-mail:\nCurrent Weight: ______ lbs or ______ kgs Height: ______ inches or ______ cms Allergies:\n\nB. INSURANCE INFORMATION\nMember ID #: Does patient have other coverage? ☐ Yes ☐ No\nGroup #: If yes, provide ID#: Carrier Name: ______________________________\nInsured: Insured: ______________________________ Insured: ______________________________\n\nC. PRESCHIBER INFORMATION\nFirst Name: Last Name: (Check one): ☐ M.D. ☐ D.O. ☐ N.P. ☐ P.A.\nAddress: City: State: ZIP:\nPhone: Fax: St Lic #: NPI #: DEA #: UPIN:\nProvider Email: Office Contact Name: Phone:\n\nD. DISPENSING PROVIDER/ADMINISTRATION INFORMATION\nPlace of Administration: Dispensing Provider/Pharmacy:\n☐ Self-administered ☐ Physician's Office ☐ Home ☐ Outpatient Dialysis Center ☐ Physician's Office\n☐ Outpatient Infusion Center Name: ☐ Retail Pharmacy ☐ Specialty Pharmacy\n☐ Home Infusion Center Phone: ☐ Mail Order ☐ Other: ______________________________\nAgency Name: Name: ______________________________\n☐ Administration code(s) (CPT): Address: Address: ______________________________\nCity: State: ZIP: ______________________________\nPhone: Fax: Phone: Fax: ______________________________\nTIN: PIN: NPI: NPI: ______________________________\nE. PRODUCT INFORMATION\nRequest is for: ☐ Riabni (rituximab-arrx) ☐ Rituxan (rituximab) ☐ Ruxience (rituximab-pvvr) ☐ Truxima (rituximab-abbs)\nDose: Directions for Use: HCPCS Code: ______________________________\nF. DIAGNOSIS INFORMATION - Please indicate primary ICD code and specify any other any other where applicable (*):\nPrimary ICD Code: ☐ Other ICD Code: ______________________________\n\nG. CLINICAL INFORMATION - Required clinical information must be completed for ALL precertification requests.\nFor Initiation Requests (clinical documentation required for all requests):\nNote: Riabni and Rituxan are non-preferred. Ruxience and Truxima are the preferred biosimilars for most indications.\nFor rheumatoid arthritis, all Rituxan and biosimilar products are non-preferred. Inflectra, Renflexis and Simponi Aria are preferred for MA plans.\nEnbrel, Humira, Idacio, Rinvoq, Tyenne SC and Xeljanz/Xeljanz XR are preferred for MAPD plans.\n☐ Yes ☐ No Has the patient had prior therapy with the requested product within the last 365 days?\n☐ No Has the patient had a trial and failure of any of the following rituximab biosimilars? (If yes, select all that apply)\n☐ ☐ Ruxience (rituximab-pvvr) ☐ Truxima (rituximab-abbs)\n☐ When was the member's trial and failure of the preferred drug? ______________________________\n☐ Please describe the nature of the failure of the preferred drug ______________________________\n☐ No Has the patient had an adverse reaction to any of the following rituximab biosimilars? (If yes, select all that apply)\n☐ ☐ Ruxience (rituximab-pvvr) ☐ Truxima (rituximab-abbs)\n☐ When was the member's adverse reaction to the preferred drug? ______________________________\n☐ Please describe the nature of the adverse reaction to the preferred drug ______________________________\nPlease explain if there are any contraindications or other medical reason(s) that the patient cannot use any of the following preferred biosimilar products when\nindicated for the patient's diagnosis? (select all that apply)\n☐ Ruxience (rituximab-pvvr) ☐ Truxima (rituximab-abbs)\n\nContinued on next page", images=[], dimensions=OCRPageDimensions(dpi=200, height=2200, width=1700)), OCRPageObject(index=2, markdown="# MEDICARE FORM\nRiabni® (rituximab-arrx),\nRituxan® (rituximab), Ruxience\n(rituximab-pvvr), Truxima (rituximab-abbs)\nMedication Precertification Request\nPage 3 of 5\n(All fields must be completed and return both pages for precertification review.)\n\nFor Medicare Advantage Part B:\nFor other lines of business:\nPlease use commercial form.\nNote: Riabni and Rituxan are non-\npreferred. The preferred biosimilar\nproducts are Ruxience and Truxima.\nFor rheumatoid arthritis, all Rituxan and\nbiosimilar products are non-preferred.\n\nPatient First Name\nPatient Last Name\nPatient Phone\nPatient DOB\n\nG. CLINICAL INFORMATION (Continued) - Required clinical information must be completed for ALL precertification requests.\nFor Initiation Requests continued (clinical documentation required for all requests):\n☐ No Has the patient had a trial and failure of any of the following? (If yes, select all that apply)\n☐ ☐ Inflectra (infliximab-dyyb) ☐ Renflexis (infliximab-abda) ☐ Simponi Aria (golimumab)\n☐ When was the member's trial and failure of the preferred drug?\n☐ Please describe the nature of the failure of the preferred drug\n☐ No Has the patient had an adverse reaction to any of the following? (If yes, select all that apply)\n☐ ☐ Inflectra (infliximab-dyyb) ☐ Renflexis (infliximab-abda) ☐ Simponi Aria (golimumab)\n☐ When was the member's adverse reaction to the preferred drug?\n☐ Please describe the nature of the adverse reaction to the preferred drug\n☐ No Has the patient had a trial and failure of any of the following? (If yes, select all that apply)\n☐ ☐ Enbrel (etanercept) ☐ Humira (adalimumab) ☐ Idacio (adalimumab-aacf) ☐ Rinvoq (upadacitinib) ☐ Tyenne SC (tocilizumab-aazg)\n☐ Xeljanz/Xeljanz XR (tofacitinib)\n☐ When was the member's trial and failure of the preferred drug?\n☐ Please describe the nature of the failure of the preferred drug\n☐ No Has the patient had a trial and failure of any of the following? (If yes, select all that apply)\n☐ ☐ Enbrel (etanercept) ☐ Humira (adalimumab) ☐ Idacio (adalimumab-aacf) ☐ Rinvoq (upadacitinib) ☐ Tyenne SC (tocilizumab-aazg)\n☐ Xeljanz/Xeljanz XR (tofacitinib)\n☐ When was the member's adverse reaction to the preferred drug?\n☐ Please describe the nature of the adverse reaction to the preferred drug\nPlease explain if there are any contraindications or other medical reason(s) that the patient cannot use any of the following preferred products when indicated for\nthe patient's diagnosis? (select all that apply)\n☐ Inflectra (infliximab-dyyb) ☐ Renflexis (infliximab-abda) ☐ Simponi Aria (golimumab)\n\nPlease explain if there are contraindications or any other medical reason(s) that the patient cannot use any of the following preferred products when indicated for\nthe patient's diagnosis? (select all that apply)\n☐ Enbrel (etanercept) ☐ Humira (adalimumab) ☐ Idacio (adalimumab-aacf) ☐ Rinvoq (upadacitinib) ☐ Tyenne SC (tocilizumab-aazg)\n☐ Xeljanz/Xeljanz XR (tofacitinib)\n\nFor All Requests (clinical documentation required for all requests):\n☐ Yes ☐ No Will Rituxan (rituximab) be used concomitantly with apremilast, tofacitinib, or other biologic DMARDs (e.g., adalimumab, infliximab)?\nAcute lymphoid leukemia\n☐ Yes ☐ No Does the patient have a documented diagnosis of Philadelphia chromosome-negative acute lymphoid leukemia (ALL)?\n☐ Yes ☐ No Is Rituxan (rituximab) being used as induction/consolidation therapy?\nAutoimmune hemolytic anemia\n☐ Yes ☐ No Does the patient have a documented diagnosis of refractory autoimmune hemolytic anemia?\nAnti-neutrophil cytoplasmic antibody-associated (ANCA-associated) vasculitides\nPlease indicate which of the following applies to the patient: ☐ Wegener granulomatosis ☐ Churg-Strauss syndrome\n☐ Microscopic polyangiitis ☐ pauci-immune glomerulonephritis\n☐ Yes ☐ No Will Rituxan (rituximab) be given in conjunction with glucocorticoids?\nAutoimmune blistering diseases, corticosteroid-refractory\n☐ Yes ☐ No Does the patient have a documented diagnosis of corticosteroid-refractory autoimmune blistering disease?\n☐ Please select which applies to the patient: ☐ pemphigus vulgaris ☐ pemphigus folliaceus ☐ bullous pemphigoid ☐ cicatricial pemphigoid\n☐ epidermolysis bullosa acquisita ☐ paraneoplastic pemphigus ☐ None of the above\nB-cell lymphomas\nPlease select which applies to the patient: ☐ AIDS-related B-cell lymphoma ☐ Burkitt lymphoma ☐ Diffuse large B-cell lymphoma ☐ Follicular lymphoma\n☐ Gastric MALT lymphoma ☐ High-grade B-Cell lymphoma ☐ Mantle cell lymphoma\n☐ Nodal marginal zone lymphoma ☐ Nongastric MALT lymphoma ☐ Primary cutaneous B-cell lymphomas\n☐ Splenic marginal zone lymphoma ☐ Other:\nContinued on next page", images=[], dimensions=OCRPageDimensions(dpi=200, height=2200, width=1700)), OCRPageObject(index=3, markdown="# MEDICARE FORM\nRiabni® (rituximab-arrx),\nRituxan® (rituximab), Ruxience\n(rituximab-pvvr), Truxima (rituximab-abbs)\nMedication Precertification Request\nPage 4 of 5\n(All fields must be completed and return both pages for precertification review.)\n\nFor Medicare Advantage Part B:\nFor other lines of business:\nPlease use commercial form.\nNote: Riabni and Rituxan are non-\npreferred. The preferred biosimilar\nproducts are Ruxience and Truxima.\nFor rheumatoid arthritis, all Rituxan and\nbiosimilar products are non-preferred.\n\nPatient First Name\nPatient Last Name\nPatient Phone\nPatient DOB\n\nG. CLINICAL INFORMATION (Continued) - Required clinical information must be completed for ALL precertification requests.\nCastleman's disease\n☐ Yes ☐ No Does the patient have a documented diagnosis of multicentric Castleman's disease (angiofollicular lymph node hyperplasia)?\nCentral nervous system lymphomas\nPlease select which applies to the patient: ☐ leptomeningeal metastases from lymphoma ☐ primary CNS lymphoma ☐ none of the above\nChronic or small lymphocytic leukemia\nPlease select which applies to the patient: ☐ chronic lymphocytic leukemia (CLL) ☐ small lymphocytic leukemia ☐ none of the above\nCryoglobulinemia\n☐ Yes ☐ No Does the patient have a documented diagnosis of cryoglobulinemia?\n☐ Yes ☐ No Is there clinical documentation that the treatment with corticosteroids and other immunosuppressive agents was ineffective?\nGraft versus host disease, chronic\n☐ Yes ☐ No Is there a documentation that Rituxan (rituximab) being used as last-resort treatment for chronic graft versus host disease (GVHD)?\nHairy cell leukemia\nPlease select which applies to the patient: ☐ relapsed hairy cell leukemia ☐ refractory hairy cell leukemia ☐ none of the above\nHeart and solid organ transplant\n☐ Yes ☐ No Is there a documentation that Rituxan (rituximab) is being used for treatment or prevention (desensitization) of highly sensitized patients with\nantibody mediated rejection in heart transplant recipients and other solid organ transplant recipients?\n☐ Please select which applies to the patient: ☐ heart transplant recipient ☐ other solid organ transplant recipient\nImmune checkpoint-inhibitor related encephalitis\nPlease identify which immune check-point inhibitor caused the encephalitis: ☐ Bavencio (avelumab) ☐ Imfinzi (durvalumab) ☐ Keytruda (pembrolizumab)\n☐ Opdivo (nivolumab) ☐ Tecentriq (atezolizumab) ☐ Yervoy (ipilimumab)\n☐ Other: _________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________", images=[], dimensions=OCRPageDimensions(dpi=200, height=2200, width=1700)), OCRPageObject(index=4, markdown="# MEDICARE FORM\nRiabni® (rituximab-arrx),\nRituxan® (rituximab), Ruxience\n(rituximab-pvvr), Truxima (rituximab-abbs)\nMedication Precertification Request\n\nFor Medicare Advantage Part B:\nFor other lines of business:\nPlease use commercial form.\n\nNote: Riabni and Rituxan are non-\npreferred. The preferred biosimilar\nproducts are Ruxience and Truxima.\nFor rheumatoid arthritis, all Rituxan and\nbiosimilar products are non-preferred.\n\nPage 5 of 5\n(All fields must be completed and return both pages for precertification review.)\n\nPatient First Name Patient Last Name Patient Phone Patient DOB\n\nG. CLINICAL INFORMATION (Continued) - Required clinical information must be completed for ALL precertification requests.\n\nRheumatoid Arthritis\nPlease indicate the severity of the patient's rheumatoid arthritis: ☐ Mild ☐ Moderate ☐ Severe\n☐ Yes ☐ No Is there evidence that the disease is active?\n☐ Yes ☐ No Will Rituxan (rituximab) be used in combination with methotrexate?\n↔☐ Yes ☐ No Was treatment with methotrexate ineffective, not tolerated or contraindicated?\n↔☐ Please select: ☐ ineffective ☐ not tolerated ☐ contraindicated\n☐ Yes ☐ No Was treatment with another conventional DMARD ineffective?\n↔☐ Please select: ☐ azathioprine ☐ cyclosporine ☐ hydroxychloroquine ☐ leflunomide ☐ sulfasalazine\n\nSjögren syndrome\n☐ Yes ☐ No Does the patient have a documented diagnosis of Sjögren's syndrome?\n☐ Yes ☐ No Was treatment with corticosteroids and other immunosuppressive agents ineffective?\n↔☐ Please provide the names and dates of the corticosteroids and other immunosuppressive agents used:\nMedication: Dates: / / /\nMedication: Dates: / / /\nThrombotic thrombocytopenic purpura\n☐ Yes ☐ No Does the patient have a documented diagnosis of refractory thrombotic thrombocytopenic purpura (TTP)?\n\nWaldenstrom's macroglobulinemia\n☐ Yes ☐ No Does the patient have a documented diagnosis of Waldenström macroglobulinemia?\n\nFor Continuation Requests:\n☐ Yes ☐ No Is this continuation request a result of the patient receiving samples of Rituxan (rituximab)?\nPlease indicate the length of time on Rituxan (rituximab): _________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________", images=[], dimensions=OCRPageDimensions(dpi=200, height=2200, width=1700))] model='mistral-ocr-2505-completion' usage_info=OCRUsageInfo(pages_processed=5, doc_size_bytes=1005317) document_annotation=None